Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.
New Orleans, La., Feb. 04, 2026 (GLOBE NEWSWIRE) -- TeleSpecialists, the nation’s largest physician-led teleneurology practice, officially unveils the TeleSpecialists TeleStroke Registry™ & The ...
Following a Mediterranean diet is associated with a lower risk of all types of stroke among women, according to a study published in Neurology Open Access. The study does not prove that the ...
Stroke is now the fourth leading cause of death among US adults, with one person dying about every 3 minutes, the latest data from the American Heart Association (AHA) show. In 2023, stroke was the ...
The largest dataset to date on stroke detection with the Swoop® system demonstrates the ability to identify small strokes rapidly and reliably, reinforcing its clinical value for acute care and ...
Expanded eligibility for advanced stroke therapies and new recommendations for diagnosing and treating stroke in children and adults are among the major updates in the new 2026 Guideline for the Early ...
Deaths from both causes are down, but they still eclipse all other causes, according to new statistics. By Nina Agrawal Despite gains in treatment, cardiovascular disease remains the leading cause of ...
A decade of CMS recognition: Practice Insights continues to simplify Merit-based Incentive Payment System reporting for providers For the tenth consecutive year, the Centers for Medicare & Medicaid ...
Voluntary participation in public reporting is associated with a slightly greater likelihood of delivering guideline-based care to patients with acute ischemic stroke, but with no major impact on ...
The AHA scientific statement details how technologic advances in AI and telehealth can support acute stroke identification and triage while emphasizing that these tools should augment, rather than ...
Following the successful completion of the NHS national pilot in April 2025, the highly anticipated first results assessing CYP2C19 genetic testing to guide clopidogrel use in ischaemic stroke and TIA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results